AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18194330 — intervention group
Group type: COMPARATOR
Intervention: 1450 ppm F-toothpaste used twice a day
Number of subjects: 215
Study 17663803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary portfolio high in plant sterols (1 g/4200 kJ), soya proteins (21.4 g/4200 kJ), soluble fibres (9.8 g/4200 kJ) and almonds (14 g/4200 kJ)
Number of subjects: 34
Study 17663803 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lovastatin
Number of subjects: 34
Study 17663803 — intervention group
Group type: COMPARATOR
Intervention: Very-low saturated fat diet (control)
Number of subjects: 34
Study 12687817 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic group (group A, n = 44) with Autoslope algorithm
Number of subjects: 87
Study 12687817 — intervention group
Group type: COMPARATOR
Intervention: Manual group (group M, n = 43) performing a walk test and using sensor-indicated rate histograms
Number of subjects: 87
Study 12687817 — intervention group
Group type: COMPARATOR
Intervention: Manual group (group M, n = 43)
Number of subjects: 87
Study 12687817 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic group (group A, n = 44)
Number of subjects: 87
Study 10767068 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleaved spiral sequence
Number of subjects: 45
Study 10767068 — intervention group
Group type: COMPARATOR
Intervention: Segmented k-space FLASH sequence
Number of subjects: 45
Study 9064372 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 85
Study 9064372 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 85
Study 1524078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg twice daily (n = 157)
Number of subjects: 317
Study 1524078 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500 mg three times daily (n = 160)
Number of subjects: 317
Study 1524078 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg twice daily
Number of subjects: 317
Study 1524078 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 500 mg three times daily
Number of subjects: 317
Study 6406442 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 or 450 mg/day)
Number of subjects: 38
Study 6406442 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (up to 200 mg/day)
Number of subjects: 38
Study 6406442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30059269 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide
Number of subjects: 50
Study 30059269 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide
Number of subjects: 50
Study 30059269 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 50
Study 29912913 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14
Number of subjects: 38
Study 29912913 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 38
Study 27294719 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain training
Number of subjects: 84
Study 27294719 — intervention group
Group type: COMPARATOR
Intervention: Single-domain training (inhibition, visuomotor function, spatial navigation)
Number of subjects: 84
Study 27294719 — intervention group
Group type: EXPERIMENTAL
Intervention: All training groups (multi-domain and single-domain)
Number of subjects: 84
Study 24386906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0
Study 24386906 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 22524802 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor list type health risk appraisal
Number of subjects: 60
Study 22524802 — intervention group
Group type: COMPARATOR
Intervention: Risk score type health risk appraisal
Number of subjects: 60
Study 19604187 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor in direct line-of-sight
Number of subjects: 31
Study 19604187 — intervention group
Group type: COMPARATOR
Intervention: Monitor perpendicular to the target
Number of subjects: 31
Study 17676423 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA (5.2 g daily)
Number of subjects: 41
Study 17676423 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 41
Study 15207999 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 146
Study 15207999 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy
Number of subjects: 146
Study 11593072 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 27
Study 11593072 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 27
Study 9673809 — intervention group
Group type: EXPERIMENTAL
Intervention: S-fluoxetine
Number of subjects: 53
Study 9673809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 8033434 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immune globulin (IVIG)
Number of subjects: 0
Study 8033434 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 0
Study 2917360 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg 4-OHA orally once, twice, and 4 times daily for 2 weeks
Number of subjects: 40
Study 2917360 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg i.m. every 2 weeks
Number of subjects: 40
Study 2917360 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg 4-OHA orally 4 times daily
Number of subjects: 40
Study 2917360 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral treatment
Number of subjects: 40
Study 2917360 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-OHA p.o.
Number of subjects: 40
Study 2917360 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-OHA i.m.
Number of subjects: 40
Study 1095081 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 62
Study 1095081 — intervention group
Group type: EXPERIMENTAL
Intervention: thioridazine
Number of subjects: 62
Study 1095081 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 62
Study 31103765 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI parameter scoring system for PS
Number of subjects: 70
Study 31103765 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI parameter scoring system for TS
Number of subjects: 70
Study 28050702 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia
Number of subjects: 25
Study 26163731 — intervention group
Group type: EXPERIMENTAL
Intervention: New computerized cognitive and social cognition program
Number of subjects: 53
Study 23685080 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner thigh Taping
Number of subjects: 191
Study 23685080 — intervention group
Group type: COMPARATOR
Intervention: Traction with a 500 mL weighted bag
Number of subjects: 191
Study 23685080 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner thigh Taping and Traction
Number of subjects: 191
Study 21131871 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - four cycles of 5-min arm ischemia/5-min reperfusion
Number of subjects: 34
Study 21131871 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure control procedure
Number of subjects: 34
Study 19244949 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.2-mm incision micro-coaxial phacoemulsification
Number of subjects: 22
Study 19244949 — intervention group
Group type: COMPARATOR
Intervention: 3.0-mm traditional coaxial phacoemulsification
Number of subjects: 22
Study 17302684 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy (preferably amiodarone)
Number of subjects: 107
Study 17302684 — intervention group
Group type: COMPARATOR
Intervention: Control group (ablation alone)
Number of subjects: 107
Study 15123391 — intervention group
Group type: EXPERIMENTAL
Intervention: Real stimulation (rTMS)
Number of subjects: 24
Study 15123391 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 11173143 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy
Number of subjects: 79
Study 11173143 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 79
Study 11173143 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiotherapy with dose escalation
Number of subjects: 79
Study 9744780 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 5‐FU 600 mg/m2 i.v. bolus (30 patients)
Number of subjects: 82
Study 9744780 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 5‐FU 600 mg/m2 bolus plus leucovorin (LV) 500 mg/m2 2‐h i.v. infusion (28 patients)
Number of subjects: 82
Study 9744780 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 5‐FU 2600 mg/m2 24‐h continuous i.v. infusion plus LV 100 mg 4‐h i.v. infusion and 50 mg orally every 4 h for five doses (24 patients)
Number of subjects: 82
Study 9744780 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients < 65 years of age)
Number of subjects: 82
Study 9744780 — intervention group
Group type: EXPERIMENTAL
Intervention: All elderly patients
Number of subjects: 82
Study 8059475 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 160
Study 8059475 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 160
Study 3059187 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 281
Study 3059187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 31714455 — intervention group
Group type: EXPERIMENTAL
Intervention: LC + SCBA
Number of subjects: 21
Study 31714455 — intervention group
Group type: EXPERIMENTAL
Intervention: LC only
Number of subjects: 21
Study 31714455 — intervention group
Group type: COMPARATOR
Intervention: PT
Number of subjects: 21
Study 31714455 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate and lactate measures
Number of subjects: 21
Study 31377776 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 962
Study 31377776 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel
Number of subjects: 962
Study 31377776 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin or transoesophageal echocardiogram prior to cardioversion
Number of subjects: 962
Study 31377776 — intervention group
Group type: EXPERIMENTAL
Intervention: No oral anticoagulation or transoesophageal echocardiogram prior to cardioversion
Number of subjects: 962
Study 31377776 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful cardioversion
Number of subjects: 962
Study 31377776 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful cardioversion
Number of subjects: 962
Study 31377776 — intervention group
Group type: COMPARATOR
Intervention: Aspirin or aspirin plus clopidogrel
Number of subjects: 962
Study 28067986 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostomy with stoma rod
Number of subjects: 151
Study 28067986 — intervention group
Group type: COMPARATOR
Intervention: Colostomy without stoma rod
Number of subjects: 151
Study 25452653 — intervention group
Group type: EXPERIMENTAL
Intervention: Coparenting breastfeeding support intervention
Number of subjects: 214
Study 25452653 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 22938679 — intervention group
Group type: EXPERIMENTAL
Intervention: Team participation (three-person teams)
Number of subjects: 57
Study 22938679 — intervention group
Group type: COMPARATOR
Intervention: Individual participation
Number of subjects: 57
Study 22938679 — intervention group
Group type: EXPERIMENTAL
Intervention: Team participation
Number of subjects: 57
Study 21203376 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 EEG derivations (F4/M1, C4/M1, O2/M1)
Number of subjects: 30
Study 21203376 — intervention group
Group type: COMPARATOR
Intervention: 1 EEG derivation (C4/M1)
Number of subjects: 30
Study 18180178 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) monotherapy
Number of subjects: 82
Study 18180178 — intervention group
Group type: COMPARATOR
Intervention: Undefined TT group
Number of subjects: 82
Study 18180178 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM)
Number of subjects: 82
Study 16527712 — intervention group
Group type: EXPERIMENTAL
Intervention: Veres intraperitoneal CO2 insufflation pressure
Number of subjects: 356
Study 14624218 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medical and conservative surgical approach
Number of subjects: 0
Study 14624218 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study 14624218 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 0
Study 12014026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 0
Study 12014026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9596598 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner safety advice plus access to low cost safety equipment for families receiving means tested state benefits
Number of subjects: 165
Study 9596598 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 165
Study 7865714 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush before biopsy
Number of subjects: 40
Study 7865714 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction cytology
Number of subjects: 40
Study 7865714 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush after biopsy
Number of subjects: 40
Study 7865714 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic biopsy
Number of subjects: 40
Study 2670728 — intervention group
Group type: EXPERIMENTAL
Intervention: COP regimen
Number of subjects: 63
Study 2670728 — intervention group
Group type: COMPARATOR
Intervention: CHOP regimen
Number of subjects: 63
Study 606768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination (200 chick cell-agglutinating units/0.5-ml dose)
Number of subjects: 2
Study 606768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (40 chick cell-agglutinating units/0.1-ml dose)
Number of subjects: 2
Study 606768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination
Number of subjects: 2
Study 606768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination
Number of subjects: 2
Study 31702015 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4)
Number of subjects: 196
Study 31702015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 30989788 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal slow‐release misoprostol (Misodel®)
Number of subjects: 196
Study 30989788 — intervention group
Group type: COMPARATOR
Intervention: Oral solution of misoprostol (Cytotec®)
Number of subjects: 196
Study 28623755 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive lacosamide (LCM)
Number of subjects: 50
Study 28623755 — intervention group
Group type: COMPARATOR
Intervention: Control group (≥2 AEDs with stable dosing)
Number of subjects: 50
Study 26308294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 50 mg twice daily for 1 week
Number of subjects: 30
Study 26308294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 30
Study 26308294 — intervention group
Group type: COMPARATOR
Intervention: Placebo 50 mg twice daily for 1 week
Number of subjects: 30
Study 26308294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23459196 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention package in intervention clinics
Number of subjects: 3538
Study 23459196 — intervention group
Group type: COMPARATOR
Intervention: Comparison clinics (control)
Number of subjects: 3538
Study 20878324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Insulin Therapy (IIT)
Number of subjects: 179
Study 20878324 — intervention group
Group type: COMPARATOR
Intervention: Conventional Insulin Therapy (CIT)
Number of subjects: 179
Study 18648227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg administered 3 min after 1.0 mg/kg rocuronium
Number of subjects: 176
Study 18648227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg administered 15 min after 1.0 mg/kg rocuronium
Number of subjects: 176
Study 18648227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg administered 3 min after 1.2 mg/kg rocuronium
Number of subjects: 176
Study 18648227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 16 mg/kg administered 15 min after 1.2 mg/kg rocuronium
Number of subjects: 176
Study 18648227 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 176
Study 18648227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 17032193 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 10,000 IU 3 x/week
Number of subjects: 40
Study 17032193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17032193 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 40
Study 14641261 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted training system for simulation of pars plana vitrectomy
Number of subjects: 14
Study 14641261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no in vitro training)
Number of subjects: 14
Study 11098741 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bridging external fixation using a small A0 external fixator
Number of subjects: 40
Study 11098741 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Kirschner wire fixation and plaster
Number of subjects: 40
Study 9262298 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA) 50 mg/day
Number of subjects: 66
Study 9262298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 66
Study 8371143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (100 mg)
Number of subjects: 9
Study 8371143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (100 mg) with alcohol (1 g/kg)
Number of subjects: 9
Study 8371143 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone (1 g/kg)
Number of subjects: 9
Study 31003194 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (computerized sessions focused on caregiver-adolescent communication, support, and monitoring)
Number of subjects: 181
Study 28657937 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 280
Study 28657937 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 280
Study 27461846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg IV
Number of subjects: 16
Study 27461846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg PO
Number of subjects: 16
Study 27461846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg (multiple dosing)
Number of subjects: 16
Study 27461846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg
Number of subjects: 16
Study 25402495 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium cyclosilicate 5 g daily for 28 days
Number of subjects: 258
Study 25402495 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium cyclosilicate 10 g daily for 28 days
Number of subjects: 258
Study 25402495 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium cyclosilicate 15 g daily for 28 days
Number of subjects: 258
Study 25402495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 22192101 — intervention group
Group type: EXPERIMENTAL
Intervention: LithoClast classic (Group 1)
Number of subjects: 69
Study 22192101 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium Laser (Group 2)
Number of subjects: 69
Study 22192101 — intervention group
Group type: EXPERIMENTAL
Intervention: StoneBreaker™ (Group 3)
Number of subjects: 69
Study 20387023 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in exercise self-efficacy
Number of subjects: 313
Study 20387023 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in health-related goal ratings
Number of subjects: 313
Study 20387023 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in walking goal ratings
Number of subjects: 313
Study 18818174 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% glucose acetated Ringer solution containing Mg2+
Number of subjects: 0
Study 18818174 — intervention group
Group type: COMPARATOR
Intervention: Glucose free solution containing Na+ 130 mEq/L without Mg2+
Number of subjects: 0
Study 16303055 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (n=11)
Number of subjects: 35
Study 16303055 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (n=24)
Number of subjects: 35
Study 12428233 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (200 mg/day)
Number of subjects: 120
Study 12428233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10323446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking duration > or = 25 cigarettes/day for more than 20 years
Number of subjects: 377481
Study 10323446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking intensity (number of cigarettes/day)
Number of subjects: 377481
Study 8935809 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ziprasidone
Number of subjects: 7
Study 8935809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1913698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR (50-200) controlled-release tablets
Number of subjects: 0
Study 1913698 — intervention group
Group type: COMPARATOR
Intervention: Standard Sinemet (25-100) immediate-release tablets
Number of subjects: 0
Study 6409316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined measles, mumps, and rubella vaccine (two different batches)
Number of subjects: 150
Study 6409316 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccination in schoolchildren aged 12
Number of subjects: 150
Study 30756250 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-sensory training (MST)
Number of subjects: 98
Study 30756250 — intervention group
Group type: COMPARATOR
Intervention: Wrist stabilization training (WT)
Number of subjects: 98